Stockcalc – Free Trial
Have a free look inside the StockCalc website at www.stockcalc.com
I have used the analysis tools on the website stockcalc.com to generate some of the content of this blog post. These tools and reports are available for free at www.stockcalc.com/TopPicks.aspx.
Undervalued Stocks on NASDAQ
Today we are looking at companies that are considered undervalued based on the Analyst data in the StockCalc database.
In the table below we can see the close price and target price for these companies along with the number of analysts covering the stock. We also have included the fiscal year for the target price as sometimes these analyst targets are not for the current or even the next fiscal year.
There can be a number of reasons why a company would be on this list. What is particularly interesting are companies with a large analyst following that make this list. We need to dig deeper into these companies to understand why the difference in price versus target.
Today’s Data on NASDAQ
Today’s data is for companies listed on the NASDAQ.
| Symbol | Name | Target Year | Close Price | Target Price Mean | Currency | Target Price # of Estimates |
|---|---|---|---|---|---|---|
| AMZN | Amazon.com Inc | 2018 | 1580.950000 | 1843.5450 | USD | 11 |
| GOOG | Alphabet Inc | 2018 | 1048.210000 | 1250.9090 | USD | 11 |
| GOOGL | Alphabet Inc | 2018 | 1051.000000 | 1250.9090 | USD | 11 |
| BKNG | Booking Holdings Inc | 2018 | 2175.710000 | 2318.3330 | USD | 6 |
| AVGO | Broadcom Inc | 2018 | 230.520000 | 324.0000 | USD | 10 |
| CHTR | Charter Communications Inc | 2018 | 276.070000 | 409.5000 | USD | 4 |
| BIIB | Biogen Inc | 2018 | 270.340000 | 341.5000 | USD | 8 |
| SHPG | Shire PLC | 2018 | 157.730000 | 219.7837 | USD | 5 |
| LRCX | Lam Research Corp | 2019 | 195.470000 | 268.2857 | USD | 7 |
| EQIX | Equinix Inc | 2018 | 403.880000 | 526.0000 | USD | 5 |
| REGN | Regeneron Pharmaceuticals Inc | 2018 | 291.250000 | 393.6667 | USD | 6 |
| MELI | MercadoLibre Inc | 2018 | 329.970000 | 400.0000 | USD | 1 |
| IAC | IAC/InterActiveCorp | 2018 | 132.420000 | 187.5000 | USD | 6 |
| SAGE | Sage Therapeutics Inc | 2018 | 148.380000 | 210.0000 | USD | 1 |
| SINA | SINA Corp | 2018 | 94.130000 | 174.0000 | USD | 1 |
| COHR | Coherent Inc | 2018 | 168.080000 | 246.0000 | USD | 3 |
| TREE | LendingTree Inc | 2018 | 259.800000 | 334.8000 | USD | 5 |
| AMWD | American Woodmark Corp | 2019 | 81.800000 | 156.0000 | USD | 1 |
| OSTK | Overstock.com Inc | 2018 | 37.650000 | 100.0000 | USD | 1 |
| VRTS | Virtus Investment Partners Inc | 2018 | 115.550000 | 173.0000 | USD | 1 |
| ADMS | Adamas Pharmaceuticals Inc | 2018 | 29.530000 | 91.0000 | USD | 1 |
| LJPC | La Jolla Pharmaceutical Co | 2018 | 30.050000 | 83.0000 | USD | 1 |
| ALBO | Albireo Pharma Inc | 2018 | 28.930000 | 92.0000 | USD | 1 |
| RTTR | Ritter Pharmaceuticals Inc | 2018 | 2.950000 | 83.7500 | USD | 2 |
| CHEK | Check-Cap Ltd | 2018 | 4.550000 | 72.0003 | USD | 1 |
Let’s look at a few companies…
Lets look at a couple of the companies on this list to get a better understanding of them.
BIIB:NAS Biogen
http://www.biogen.com
Biogen has 7300 employees and is headquartered in United States.
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.
SHPG:NAS Shire
http://www.shire.com
Shire has 23044 employees and is headquartered in Ireland.
Shire PLC is a biotechnology company focused mainly in the research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines for patients with rare diseases and other select conditions.
Free Valuation
Run a valuation on any of the companies listed above at www.stockcalc.com/valureport.aspx or subscribe at our Stockcalc Facebook Page to receive this list each day Stockcalc Reports.
The content presented here is in part from the website stockcalc.com and is provided on an as is or as available basis with all faults and may not be current in all cases. You should not rely on any of the information as authoritative or as a substitute for the exercise of your own skill and judgment in making an investment decision.